Shanghai Gene Therapy Company Vitalgen, With Over RMB 1 Billion in Cash, Gears Up for IPO

On June 17, 2026, the Shanghai Stock Exchange accepted Vitalgen's application for listing on the STAR Market, with a planned fundraising target of RMB 2.5 billion. The company holds three gene therapy pipelines nearing commercialization: enrollment for the Phase III trial of VGN-R09b for AADC deficiency was completed in July 2025; enrollment for the trial of VGR-R01 for crystalline retinal degeneration was completed during the same period; and the Phase I/II clinical trial of VGN-R09b for Parkinson's disease has been completed.

Against the backdrop of the gene therapy sector having just undergone a round of bubble-bursting and consolidation, what narrative is this IPO actually telling?

The story begins with a little-known disease.

AADC deficiency, fully known as aromatic L-amino acid decarboxylase deficiency, is a rare hereditary neurological disorder. Children with the condition are unable to normally synthesize the neurotransmitters dopamine and serotonin, leading to severe motor developmental delays, hypotonia, recurrent oculogyric crises, and intractable dystonic episodes starting from infancy.

Prior to this, Upstaza from PTC Therapeutics was the only approved therapy globally, priced at approximately $3.7 million per year. For families of affected children in China, this is an unattainable figure.

Vitalgen has chosen AADC deficiency as its first therapeutic target. In July 2025, the Phase III clinical trial of VGN-R09b completed enrollment, with 13 pediatric patients receiving treatment. Key results were repeatedly highlighted in the prospectus: 12 months after administration, all 13 subjects achieved the milestone of complete "head control," 10 (76.9%) reached the milestone of "independent sitting," and one patient attained the higher milestone of "standing with support."

This is not an easily achievable benchmark. According to clinical data for PTC Therapeutics' Upstaza, only 8 out of 12 patients (67%) achieved head control after 48 weeks of treatment. Vitalgen's data surpasses that of marketed products, with a faster onset of action—five pediatric patients achieved head control within 12 weeks post-dosing.

The technical rationale behind VGN-R09b involves using adeno-associated virus (AAV) vectors to directly deliver the functional DDC gene to the striatum in the brain, thereby restoring neurons' ability to synthesize dopamine. This represents a "root-cause" therapeutic approach—rather than supplementing with exogenous dopamine precursors (levodopa), it repairs the patient's own neurotransmitter synthesis system.

But the logic behind this goes far beyond simply "developing a drug for a rare disease."

As VGN-R09b navigated the regulatory pathway for its indication in AADC deficiency, the same molecule was being developed for a vastly different battlefield: Parkinson's disease.

Clinical data from Phase I/II trials for Parkinson's disease, released in late 2024, showed that 14 patients with primary Parkinson's disease received VGN-R09b treatment. At the 26-week follow-up point, the low-dose group demonstrated a mean improvement of 37% in UPDRS Part III scores (motor function assessment, where lower scores indicate better outcomes) compared to baseline, while the high-dose group showed a 35.9% improvement. This represents a clinically meaningful result, as UPDRS Part III is regarded as a core motor function endpoint in Parkinson's disease clinical trials, and an improvement exceeding 30% is generally considered to translate into tangible improvements in quality of life.

More importantly, imaging data provided direct evidence. The significant increase in intracerebral 18F-Dopa PET signal values after treatment is a direct marker of the recovery of dopaminergic neuron function.

Parkinson's disease and AADC deficiency share a common molecular target—the dopamine synthesis pathway. AADC is the key enzyme responsible for converting levodopa into dopamine; the shared defect in both diseases lies in insufficient AADC activity, albeit with differing severity and clinical manifestations. This provides the biological rationale for VGN-R09b's "one molecule, two indications" strategy.

However, the market size for Parkinson's disease is not in the same league as that for AADC deficiency. The number of Parkinson's patients in China has reached millions and continues to grow with population aging. This is the truly substantial market capable of supporting valuations.

The greater differentiation lies in the dual-target approach. VGN-R09b employs an AAV dual-gene expression strategy, simultaneously delivering the genes for AADC and GDNF (glial cell line-derived neurotrophic factor). GDNF is a neuroprotective factor that has been studied for many years and can support the survival and functional maintenance of dopaminergic neurons.

This design endows VGN-R09b with a dual mechanism of "enzyme replacement + neuroprotection," granting it "First-in-Class" potential.

In the global field of gene therapy for Parkinson's disease, Vitalgen is currently on par with AskBio, a subsidiary of Bayer. Vitalgen expects to initiate Phase III clinical trials in China and clinical trials in the United States in the second half of 2026, with the goal of obtaining marketing approval in China by 2029.

If primary Parkinson's disease represents a large market encompassing millions of patients, another niche segment within the Parkinson's landscape is even more distinctive—GBA1-mutant Parkinson's disease. This is a hereditary parkinsonian syndrome caused by mutations in the GBA1 gene, with an estimated 420,000 patients in China in 2025. VGN-R08b is a product specifically designed for this patient population and is the first gene therapy drug targeting GBA1-mutant Parkinson's disease to enter clinical trials in China. In October 2025, VGN-R08b received Orphan Drug Designation from the FDA.

A rare Parkinson's disease, an even rarer Parkinson's disease. Vitalgen's strategic layout in the Parkinson's field is clear: first, leverage dual-target technology to secure a commanding position in primary Parkinson's disease, then penetrate a less competitive, higher-barrier market through the precise niche of GBA1 mutations.

The underlying strategic calculus is: in an era when gene therapy cannot yet serve as a "one-size-fits-all" cure, how to leverage a portfolio of pipeline assets to hedge against uncertainty.

To understand Vitalgen, one must look not only at its pipeline but also at its underlying technology.

In the field of gene therapy, delivery and editing are the two most core capabilities; whoever masters them holds the power to define this sector.

Vitalgen's delivery systems are divided into two platforms. One is the ViVec platform, based on AAV (adeno-associated virus), which represents the most mature viral vector technology in the global gene therapy field, with multiple commercialized products validating its safety and efficacy. The other is the ViLNP platform, based on LNP (lipid nanoparticles), a non-viral vector technology expected to overcome the limitations of AAV regarding cargo size and repeat dosing, demonstrating significant potential in mRNA vaccines and in vivo gene editing.

Vitalgen's CLAMP antibody-conjugated LNP platform enables modular replacement of targeting ligands for precise delivery to hematopoietic stem cells, immune cells, and even the central nervous system.

The gene editing system is Vitalgen's true "technological moat." Its ViCas precision editing platform is based on the AaCas12bMax gene editing system, a foundational technology developed by the Institute of Zoology, Chinese Academy of Sciences, and the Beijing Institute for Stem Cell Research. Through in-depth collaborations with these two research institutions, Vitalgen has secured patent licenses and carried out systematic engineering optimizations on this basis.

The native AaCas12b system exhibits low activity in mammalian cells under natural conditions, making it difficult to meet the requirements for industrialization.

Vitalgen has comprehensively optimized the sequence and structure while preserving its inherently low off-target profile, ultimately increasing editing efficiency by one to two orders of magnitude in clinical application scenarios. In primary cells such as hematopoietic stem cells and T cells, editing efficiency consistently exceeds 90%.

A key statistic is that, at the whole-genome scale, AaCas12bMax exhibits virtually no detectable off-target events, with the incidence of chromosomal translocations and large-scale structural variations reduced by approximately an order of magnitude compared to the Cas9 system. This represents its core advantage over Cas9: in therapeutic strategies requiring simultaneous multi-locus editing or long-term in vivo activity, differences in safety profiles may determine the success or failure of a product.

Of particular note, the AaCas12b system originates from a domestic Chinese research institution. This means that Vitalgen's gene-editing technology platform inherently avoids the dense web of patent traps laid by U.S. research institutions and multinational corporations within the core Cas9 patent landscape.

In the current geopolitical landscape, "autonomy and controllability" is not a slogan but a genuine business moat.

Even more intriguing is the commercialization path of the technology platform.

The prospectus disclosed that technologies such as LNP and AaCas12bMax have been licensed out in multiple fields, including in vivo CAR-T, TIL, UCAR-T, and tumor vaccines. Technology licensing revenue amounted to RMB 2.12 million in 2024 and surged to RMB 19.45 million in 2025. Therorna contributed RMB 9.24 million, GRIT Biotechnology RMB 7.63 million, and Imunopharm RMB 1.71 million.

In other words, Vitalgen is not just a biotech company; it also engages in technology licensing. This represents a fundamental departure from the traditional biotech model driven by fundraising and pipeline advancement. It simultaneously assumes the role of a "water seller," sharing R&D costs, validating technological reliability, and building an industrial ecosystem by providing foundational tools to industry peers.

The rapid ramp-up in technology licensing revenue is a noteworthy signal. In 2025, it increased nearly tenfold compared to 2024, and is expected to continue rising significantly in 2026. If this trend persists, revenue from technology licensing will gradually emerge as Vitalgen's second growth curve, reshaping the market's stereotype that gene therapy companies have "pipelines but no revenue."

RMB 2.5 billion raised in the IPO: These are the stakes in Vitalgen's gamble.

The prospectus disclosed in detail the use of proceeds: RMB 1.667 billion is planned for new drug R&D projects, RMB 150 million for technology platform development projects, RMB 275 million for the construction of Vitalgen's headquarters and R&D center, RMB 261 million for the expansion and renovation of Taichang Bio's commercial production base, and RMB 150 million to supplement working capital.

VGN-R09b represents the largest capital pool. This molecule simultaneously targets two indications: AADC deficiency and Parkinson's disease. The combined clinical development costs, both domestically and internationally, are estimated at approximately RMB 1.4 billion. This is a staggering figure and a monumental commitment—if the Phase III clinical trial for Parkinson's disease fails, or if the reimbursement system cannot accommodate a gene therapy product priced in the millions, this investment will be lost entirely.

VGR-R01 is another key bet. It is a gene therapy drug targeting Bietti crystalline dystrophy (BCD). Phase III clinical trial enrollment was completed in March 2025, and the NDA submission is expected in 2026. If approved, it will become the first globally approved BCD therapeutic, filling a significant unmet clinical need.

BCD is a progressive retinal dystrophy characterized by gradual vision loss leading to blindness, for which there are currently no effective treatments worldwide. VGR-R01 has received Breakthrough Therapy Designation from the CDE, Orphan Drug Designation from the FDA, and Priority Medicines Status from the EMA, as well as qualification for the CDE's "Care Program" pilot project—demonstrating regulatory endorsement of this product through concrete actions.

Commercialization preparations are underway.

The prospectus discloses that the company has obtained a Drug Manufacturing License and possesses low-cost production capabilities at commercial scale. Taking VGR-R01 as an example, it is possible to produce 1,000 doses at a cost in the million-yuan range, which means that the production cost per single dose for each patient can be controlled at the thousand-yuan level.

This is a critical figure. The high pricing of gene therapies has long been one of the most contentious issues in the industry. PTC Therapeutics' Upstaza is priced at approximately $3.7 million in Europe and the United States, and PTC's financial reports indicate that its commercialization path has not been smooth. Vitalgen clearly recognizes that if production costs cannot be reduced, even the most robust clinical data may face reimbursement hurdles. Vitalgen's proposed strategies include exploring innovative payment models such as outcome-based pricing, striving for inclusion in the national basic medical insurance and commercial health insurance formularies, and promoting the development of a diversified payment system.

However, these explorations have yet to be implemented. For a company that will not have products on the market until 2027, building a payment system is a more prolonged and complex challenge than clinical development.

The competitive landscape is another dimension for understanding Vitalgen.

In the field of AADC deficiency, PTC Therapeutics' Upstaza has been approved for marketing in Europe and the United States, with Vitalgen being the fastest-moving domestic follower. The key to competition lies not in who crosses the finish line first, but in who can achieve better accessibility in the Chinese market. With Upstaza priced at $3.7 million, it holds virtually no commercial feasibility in China. If Vitalgen secures approval at a significantly lower price point, it will address a substantial unmet need.

In the field of Parkinson's disease, Vitalgen is running neck-and-neck with Bayer/AskBio. This represents a global competition, as well as a simultaneous race across the Chinese and U.S. regulatory systems. Vitalgen's unique advantages lie in being the first domestic gene therapy product for Parkinson's disease to enter registrational clinical trials, while also targeting two niche markets: idiopathic Parkinson's disease and GBA1-mutant Parkinson's disease—the latter being the first product in China to enter clinical development for this indication.

In the BCD field, Vitalgen is the first investigational product globally to enter Phase III clinical trials and is poised to become the first approved BCD therapeutic worldwide. CHIGENOVO is catching up, but still lags in progress.

In the field of neuronopathic Gaucher disease, Vitalgen's investigational product is the only one globally to have entered clinical trials. The value of this "global first" lies in the fact that it has no comparable competitors, its pricing system must be built from scratch, and it is the sole player at the negotiating table with payers.